ZUG, Switzerland, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ...

Oculis' main value driver appears to be OCS-01, which targets a respectable $4 billion DME TAM with its non-invasive eye drops. Eye injections are tough on patients, so this bodes well for OCS-01 ...

So should Oculis Holding (NASDAQ:OCS) shareholders be worried about its cash burn? In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the ...

Oculis Holding AG issued 2.5 million treasury shares, maintaining 7.2% of total registered shares, under an ATM program. Oculis Holding AG, a biopharmaceutical company based in Zug, Switzerland ...

ZUG, Switzerland, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) ("Oculis" or the "Company"), a global biopharmaceutical company, has ...

ZUG, Switzerland, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares of ...

Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly. So should Oculis Holding (NASDAQ:OCS) shareholders be worried about its cash burn? In this ...

Please provide your email address to receive an email when new articles are posted on . KOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2025, Riad Sherif, MD, CEO of Oculis ...